Table 2.
Values for Primary Exposures at the Index Visit by HIV Status in 2,527 Multicenter AIDS Cohort Study (MACS) and 2,446 Women's Interagency HIV Study (WIHS) Participants
| |
MACS |
WIHS |
|||
|---|---|---|---|---|---|
| FINDRISC components | Risk points | HIV positive (n = 1,299) | HIV negative (n = 1,228) | HIV positive (n = 1,841) | HIV negative (n = 605) |
| Age, n (%) | |||||
| <45 years | 0 | 823 (63) | 557 (45) | 1,186 (64) | 432 (71) |
| 45 to <55 years | 2 | 392 (30) | 437 (36) | 549 (30) | 138 (23) |
| 55 to 65 years | 3 | 84 (6) | 234 (19) | 106 (6) | 35 (6) |
| Body mass index, n (%) | |||||
| <25 kg/m2 | 0 | 686 (53) | 531 (43) | 607 (33) | 190 (31) |
| 25 to <30 kg/m2 | 1 | 460 (35) | 488 (40) | 552 (30) | 145 (24) |
| ≥30 kg/me | 3 | 153 (12) | 209 (17) | 682 (37) | 270 (45) |
| Waist circumference, n (%) | |||||
| Men <37.0 inches, women <31.5 inches | 0 | 888 (68) | 681 (55) | 424 (23) | 166 (27) |
| Men 37.0 to <40.2, women 31.5 to <34.6 | 3 | 246 (19) | 266 (22) | 387 (21) | 106 (18) |
| Men ≥40.2 inches, women ≥34.6 inches | 4 | 165 (13) | 281 (23) | 1,030 (56) | 333 (55) |
| Fasting blood glucose, n (%) | |||||
| <5.55 mmol/L | 0 | 1,057 (81) | 1,029 (84) | 1,650 (90) | 555 (92) |
| 5.55 to <6.99 mmol/L | 5 | 242 (19) | 199 (16) | 191 (10) | 50 (8) |
| History of HTN medication, n (%) | |||||
| No | 0 | 1,166 (90) | 1,089 (89) | 1,469 (80) | 521 (86) |
| Yes | 2 | 133 (10) | 139 (11) | 372 (20) | 84 (14) |
| FINDRISC score, median (IQR)a | 3 (0–6) | 4 (1–7) | 6 (4–8) | 6 (3–7) | |
| HOMA-IR, median (IQR) | 2.5 (1.8–3.7) | 2.2 (1.6–3.3) | 2.1 (1.3–3.6) | 1.7 (1.1–3.2) | |
Index visit defined as the first visit at which fasting blood glucose, hemoglobin A1c, self-reported antidiabetic medication use, and self-reported diabetes data were concurrently available.
a
Score ranges from 0 to 17. Higher scores reflect higher risk for developing drug-treated diabetes.
HTN, hypertension; FINDRISC, Finnish Diabetes Risk Score; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance.